Liver cancer cell line with LAPTM5 gene stably knocked out as well as construction method and application of liver cancer cell line

The construction of a stable LAPTM5 gene knockout hepatocellular carcinoma cell line using the CRISPR/Cas9 system addresses the shortcomings in hepatocellular carcinoma model construction and provides an ideal model for autophagy and drug resistance research.

CN119040323APending Publication Date: 2024-11-29ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411173600.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

There is a lack of suitable liver cancer models to study the role of LAPTM5 in autophagy and drug resistance, and existing technologies cannot effectively construct liver cancer cell lines with stable knockout of the LAPTM5 gene.

Method used

Using the CRISPR/Cas9 system combined with sgRNA targeting the LAPTM5 gene, specific sgRNA primers were designed and a CRISPR/Cas9 vector was constructed to knock out the LAPTM5 gene in the HCC-LM3 cell line, thus constructing a stable HCC-LM3-LAPTM5 knockout cell line.

Benefits of technology

A stable LAPTM5 gene knockout hepatocellular carcinoma cell line was successfully constructed, and under normal culture conditions, it had no significant effect on cell proliferation and apoptosis, providing an ideal research model for autophagy and drug resistance studies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040323A_ABST
    Figure CN119040323A_ABST
Patent Text Reader

Abstract

The invention discloses a liver cancer cell line with LAPTM5 gene stably knocked out as well as a construction method and application of the liver cancer cell line. According to the invention, sgRNA of specific targeting human LAPTM5 is firstly designed, and the LAPTM5 gene of a human liver cancer cell line HCC-LM3 is successfully knocked out by virtue of a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) technology. Protein expression is detected through Western blot, and it is proved that the knockout cells are successfully constructed. Meanwhile, experiments prove that the LAPTM5 knockout has no obvious influence on the processes of proliferation, apoptosis and the like of cells under normal culture conditions. The HCC-LM3-LAPTM5 knockout cell line constructed by the invention plays a biological role by inhibiting a cell autophagy process, and the cell line is suitable for basic clinical cross correlation researches based on autophagy, drug resistance and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention discloses a liver cancer cell line with a stable knockout of a LAPTM5 gene and a construction method and application thereof, belonging to the technical field of bioengineering. Background Art

[0002] LAPTM5 (Lysosomal-associated transmembrane protein 5), also known as CD40-linker-activated specific transcript 6 (CLAST6), is a transmembrane protein located in late endosomes and lysosomes, and its encoding gene is located on chromosome 1p34. LAPTM5 belongs to the late endosomal / lysosomal transmembrane protein family and was originally identified as a protein homology regulator and inflammatory signaling pathway regulator. LAPTM5 plays a vital role in the regulation of cellular autophagy. Autophagy comes from the Greek meaning of "eating oneself" and was first coined by Christian de Duve. There are three types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy, all of which promote proteolytic degradation of cytoplasmic components in lysosomes. Autophagy plays an important role in the occurrence and development of tumors.

[0003] LAPTM5 participates in the transport of proteins from the Golgi apparatus to the lysosomes, and affects the sorting of lysosomes and cytoplasmic membranes by interacting with the E3 ubiquitin ligase Nedd4. For example, in liver cancer research, LAPTM5 can mediate drug resistance by regulating cell autophagy. HCC-LM3 cells are a liver cancer cell line that is inoculated into nude mice by the human liver cancer cell line MHCC97-H, screened for lung metastasis three times, and constructed by taking lung metastases to establish highly spontaneous lung metastasis after subcutaneous inoculation. HCC-LM3 cells are widely used in basic and clinical research on the pathogenesis of human liver cancer, and can also be used for anti-tumor drug screening. However, there is still a lack of suitable liver cancer models to study autophagy. Summary of the invention

[0004] The purpose of the present invention is to provide a liver cancer cell line with a stable knockout of the LAPTM5 gene and a construction method and application thereof. The HCC-LM3-LAPTM5 knockout cell line constructed by the present invention exerts a biological effect by inhibiting the cell autophagy process. The cell line is suitable for basic clinical cross-correlated studies based on autophagy, drug resistance, etc.; the present invention has been functionally verified, and under normal culture conditions, LAPTM5 knockout has no significant effect on the proliferation and apoptosis of the cell line.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions:

[0006] In a first aspect of the present invention, a sgRNA for targeted knockout of the LAPTM5 gene in a liver cancer cell line is provided, wherein the synthetic primer of the sgRNA comprises a forward primer having a sequence as shown in SEQ ID NO: 2 and a reverse primer as shown in SEQ ID NO: 3.

[0007] The second aspect of the present invention provides a biological material comprising the sgRNA described in the first aspect, wherein the biological material is one or more of a vector, an expression cassette or a transgenic cell.

[0008] The third aspect of the present invention provides the use of the sgRNA described in the first aspect or the biomaterial described in the second aspect in the preparation of a reagent or a kit for constructing a liver cancer cell line with stable knockout of the LAPTM5 gene.

[0009] In a fourth aspect of the present invention, a method for constructing a liver cancer cell line with stable knockout of the LAPTM5 gene is provided, comprising: knocking out the LAPTM5 gene of the liver cancer cell line using a CRISPR / Cas9 system, wherein the CRISPR / Cas9 system uses the sgRNA according to claim 1, and the liver cancer cell line is HCC-LM3 cells.

[0010] In some embodiments of the present invention, the method specifically comprises the following steps:

[0011] Step 1): Design a pair of complementary primers for sgRNA targeting the first exon region of the human LAPTM5 gene to synthesize the target sgRNA, linearize the vector PGMLV-GM1 by restriction endonuclease, connect the target sgRNA, and construct a CRISPR / Cas9 vector with the target sgRNA, wherein the primer of the sgRNA includes a forward primer having a sequence as shown in SEQ ID NO: 2 and a reverse primer as shown in SEQ ID NO: 3;

[0012] Step 2): The CRISPR / Cas9 vector with the target sgRNA constructed in step 1) is transformed into competent cells; the transformants are screened by colony PCR, and positive clones are identified and screened by sequencing, and the positive clones are amplified and the plasmids are extracted;

[0013] Step 3): The plasmid extracted in step 2) is combined with a virus packaging helper plasmid to form a three-plasmid lentiviral system and co-transfected into 293T cells for virus packaging to obtain LAPTM5-sgRNA-Puro lentivirus;

[0014] Step 4): Transfect HCC-LM3 cells with Cas9-Blastin lentivirus to construct HCC-LM3-Cas9 monoclonal cell line;

[0015] Step 5): The HCC-LM3-Cas9 monoclonal cell line is transfected with the LAPTM5-sgRNA-Puro lentivirus obtained in step 3), positive cells are screened using puromycin, and monoclonal cells are isolated and cultured to obtain a liver cancer cell line with stable knockout of the LAPTM5 gene.

[0016] The fifth aspect of the present invention provides a liver cancer cell line with stable knockout of the LAPTM5 gene constructed by the construction method described in the third aspect.

[0017] The sixth aspect of the present invention provides the use of the liver cancer cell line with stable knockout of the LAPTM5 gene described in the fourth aspect in constructing a LAPTM5 gene function research model.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] The present invention designs sgRNA for targeted knockout of the target gene by the CRISPR / Cas9 system based on the first exon region of the human LAPTM5 gene, and further successfully constructs a HCC-LM3-LAPTM5 stable knockout cell line using sgRNA. It is also verified through experiments that under normal culture conditions, LAPTM5 knockout has no significant effect on cell proliferation, apoptosis and other processes. This model does not affect the cell state under normal culture conditions and can serve as an ideal model for studying cell autophagy. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a plasmid structure diagram of the CRISPR / Cas9 vector.

[0021] Figure 2 Western blot was used to detect the LAPTM5 knockout level and its effect on apoptosis of cell lines.

[0022] Figure 3 The CCK8 experiment was used to detect the effect of LAPTM5 on the proliferation ability of HCC-LM3. DETAILED DESCRIPTION

[0023] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.

[0024] The experimental methods in the following examples without specifying specific conditions were carried out according to conventional methods and conditions, or selected according to the product instructions; the materials, reagents, etc. used were conventional commercially available products unless otherwise specified.

[0025] Example

[0026] Construction of HCC-LM3-LAPTM5 knockout cell line:

[0027] 1. Vector construction:

[0028] The vector PGMLV-GM1 was linearized by restriction endonuclease and connected to the target gRNA to construct a CRISPR / Cas9 vector with the target gRNA sequence. The vector plasmid map is shown in Figure 1 As shown, the specific steps are as follows:

[0029] 1) gRNA sequence design

[0030] The sgRNA sequence was designed according to the first exon region of the human LAPTM5 gene, and its targeting sequence was: 5'-CACACTCACCACATGGTAGA-3' (SEQ ID NO: 1).

[0031] 2) Annealing of gRNA

[0032] gRNA oligo is as follows:

[0033] Primer-T:5'-CACCGCACACTCACCACATGGTAGA-3' (SEQ ID NO: 2);

[0034] Primer-B: 5'-AAACTCTACCATGTGGTGAGTGTGC-3' (SEQ ID NO: 3);

[0035] Dilute the primers with sterile TE buffer to a final concentration of 100 μM. Pipette 10 μl of the upstream and downstream primers, mix them, pipette evenly, and place them in a PCR tube for annealing. The procedure is as follows:

[0036] 95℃30s;

[0037] 72℃2min;

[0038] 37℃2min;

[0039] 25℃2min;

[0040] After completion, place on ice for a few minutes and connect directly or store in a freezer at -20°C.

[0041] 3) Enzyme digestion and recovery of CRISPR / Cas9 vector

[0042] The enzyme digestion system is as follows:

[0043]

[0044] Digest at 37℃ for 30min. During this period, prepare 0.8% agarose gel and perform nucleic acid electrophoresis after digestion. After electrophoresis, cut the gel strip containing the target fragment. Weigh the total weight with a balance and subtract the weight of the empty tube to calculate the weight of the gel. Calculate the volume of the gel based on 100mg being approximately 100μl, and add 3 times the volume of the gel to QG buffer and place it in a 50℃ water bath to melt the gel completely. Shake the EP tube appropriately during this period to accelerate the dissolution of the gel. After the gel is completely melted, add isopropanol equal to the volume of the gel and mix well. Transfer all the above liquids to the filter column and centrifuge at 13000rpm for 30s. Discard the liquid in the tube, add 750μl of PE buffer to the column, and centrifuge for 1min. Discard the liquid in the tube and empty it again for 1min. Change to a new 1.5ml EP tube, add 50μl of EB buffer to the column, centrifuge for 1min, and the centrifuge tube is the recovered vector.

[0045] 4) Ligation of CRISPR / Cas9 vector and primers

[0046] The connection system is as follows:

[0047]

[0048]

[0049] Incubate in a 25°C water bath for 30 min.

[0050] 5) Transformation of ligation products and identification of colony PCR, extraction of plasmids

[0051] Place the competent cells DH5α on ice and wait for them to thaw naturally. Add all the above ligation products to the competent cells, place them on ice for 20 minutes, and then heat shock them in a 42°C water bath for 90 seconds. Then quickly place them on ice for 2-3 minutes. Add 1000μl of LB culture medium without antibiotics and culture at 37°C, 150rpm shaking for 45 minutes. Centrifuge at 3000rpm for 2 minutes, discard about 850μl of supernatant, blow and disperse the bacterial liquid at the bottom of the tube, add it to the culture dish containing the corresponding resistance, spread it evenly with a sterilized applicator, and invert it in a 37°C constant temperature incubator for overnight culture. Pick several single colonies and perform small-scale shaking culture. Sequencing identifies positive clones and extract plasmids for subsequent virus packaging (see Section 3.1 below).

[0052] 2. Construction of HCC-LM3-Cas9 monoclonal cell line:

[0053] 1) Cas9-Blastin lentivirus (lenticas9-Blast) transfected HCC-LM3 (no serum, no dual antibody, added 2μg / μl polybrene);

[0054] 2) After 8 h, replace with complete medium;

[0055] 3) After 48 h, add Blastin to a final concentration of 5000 μg / μl and screen for 5-7 days;

[0056] 4) The screened cell lines were plated into 96-well plates by limiting dilution method until each well contained only one cell;

[0057] 5) After successful monoclonal screening, it is used for subsequent transfection of sgRNA to knock out LAPTM5.

[0058] 3. Construction of HCC-LM3-LAPMT5-KO cell line:

[0059] 1. Packaging of LAPTM5-sgRNA-Puro lentivirus:

[0060] 1) 293T cell division

[0061] One day before transfection, the grown 293T cells were subcultured into 10 cm culture dishes at appropriate ratios, and transfection was prepared when the cells grew to 70% to 80%.

[0062] 2) Transfection

[0063] Take a sterile 1.5mL EP tube or 15mL centrifuge tube and prepare the transfection system according to the following table:

[0064] Tube A:

[0065] Reduced serum medium: opti-MEM 500μl Plasmid (plasmid extracted in the previous step) 5μg Lentivirus auxiliary packaging plasmid: pCAG-dR8.95μg+VSV-G5μg 10μl(10μg) Transfection reagent: p3000 30μl

[0066] Tube B:

[0067] Reduced serum medium: opti-MEM 500μl Transfection reagent: lipo3000 15μl

[0068] Tube A and Tube B were allowed to stand at room temperature for 5 minutes, then mixed and placed at room temperature for 15-20 minutes, then evenly added to the 293T cell culture dish to be transfected (final volume 5 ml), and then placed in a CO2 incubator for culture.

[0069] 3) Change the fluid

[0070] 8 hours after transfection, carefully aspirate the cell culture medium and discard it into a waste liquid cup containing disinfectant, then add 10 ml of fresh complete cell culture medium and continue culturing.

[0071] 4) Virus collection

[0072] After 48 hours of fluid replacement, aspirate the cell supernatant into a 50 ml centrifuge tube and centrifuge at 4°C, 4000g for 5 min. Filter the supernatant with a 0.22 μm filter and transfer to a new centrifuge tube. Finally, transfer the filtrate to a concentrator in batches and centrifuge at 4°C, 3500g for 10 min. Discard the lower layer of liquid into a waste liquid cup containing disinfectant. Centrifuge for the last time at 4°C, 3500g for 20 min. At this time, the liquid in the upper layer of the filter is the virus concentrate.

[0073] 6) Virus packaging and storage

[0074] The virus was aliquoted and stored at -80°C.

[0075] 2. Lentiviral transfection of HCC-LM3-Cas9 cells to knock out LAPTM5 gene

[0076] 1) The above LAPTM5-sgRNA-Puro lentivirus was transfected into the HCC-LM3-Cas9 cell line (without serum, without double antibody, and adding 2 μg / μl polybrene);

[0077] 2) Replace complete medium after 8 hours;

[0078] 3) After 48 hours, Puro was added to a final concentration of 5 μg / μl and screened for 5-7 days;

[0079] 4) The screened cell lines were plated into 96-well plates by limiting dilution method until there was only one cell in one well, and single clones were cultured.

[0080] 4. Western blot verification

[0081] 1) Collect the above-mentioned single cell clone cell lines and lyse the cells by incubating on ice for 15 minutes using RIPA protein lysis buffer;

[0082] 2) Collect the cell lysate, centrifuge at 4°C, 12000 rpm for 15 min, and collect the supernatant;

[0083] 3) Add protein loading buffer in proportion and heat at 100°C or in a boiling water bath for 10 min to fully denature the protein;

[0084] 4) Western blot was used to detect the expression of LAPTM5 protein. Figure 2 As shown, it indicates the successful construction of HCC-LM3-LAPTM5 knockout cell line.

[0085] 5. Functional Verification:

[0086] 1) Cleaved-Caspase9 protein is a protein formed after Caspase9 protein is cleaved. Caspase9 can be activated by self-cleavage and apoptotic body (a protein complex composed of cytochrome c and apoptotic peptidase activating factor 1); therefore, in this example, the expression of Cleaved-Caspase9 protein was detected by Western blot to detect the effect of knocking out LAPTM5 on cell apoptosis in HCC-LM3. Figure 2 As shown in the results, under normal culture conditions, knocking out LAPTM5 in HCC-LM3 had no significant effect on cell apoptosis, which was specifically manifested by the fact that there was no significant difference in the Cleaved-Caspase9 protein between the two groups. Therefore, under normal culture conditions, knocking out LAPTM5 had no significant effect on the apoptosis of the liver cancer cell line HCC-LM3, and it can be used as a reliable model for studying cell autophagy.

[0087] 2) The effect of LAPTM5 on the proliferation ability of HCC-LM3 was detected by CCK8 experiment. Figure 3 As shown, under normal culture conditions, knocking out LAPTM5 in HCC-LM3 had no significant effect on the proliferation ability of cells.

[0088] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.

Claims

1. A sgRNA for targeted knockout of the LAPTM5 gene in liver cancer cell lines, It is characterized in that The synthetic primers for the sgRNA include a forward primer whose sequence is shown in SEQ ID NO: 2 and a reverse primer whose sequence is shown in SEQ ID NO:

3.

2. A biological material comprising the sgRNA according to claim 1, It is characterized in that The biological material is one or more of a vector, an expression cassette or a transgenic cell.

3. Use of the sgRNA according to claim 1 or the biomaterial according to claim 2 in the preparation of a reagent or a kit for constructing a liver cancer cell line with stable knockout of the LAPTM5 gene.

4. A method for constructing a liver cancer cell line with stable knockout of LAPTM5 gene, It is characterized in that include: The LAPTM5 gene of a liver cancer cell line is knocked out using a CRISPR / Cas9 system, wherein the CRISPR / Cas9 system uses the sgRNA of claim 1, and the liver cancer cell line is HCC-LM3 cells.

5. The construction method according to claim 4, It is characterized in that The method specifically comprises the following steps: Step 1): Design a pair of complementary primers for sgRNA targeting the first exon region of the human LAPTM5 gene for synthesizing the target sgRNA, linearize the vector PGMLV-GM1 by restriction endonuclease, connect the target sgRNA, and construct a CRISPR / Cas9 vector with the target sgRNA, wherein the primers for the sgRNA include a forward primer having a sequence as shown in SEQ ID NO: 2 and a reverse primer as shown in SEQ ID NO: 3; Step 2): The CRISPR / Cas9 vector with the target sgRNA constructed in step 1) is transformed into competent cells; the transformants are screened by colony PCR, and positive clones are identified and screened by sequencing, and the positive clones are amplified and the plasmids are extracted; Step 3): The plasmid extracted in step 2) is combined with a virus packaging helper plasmid to form a three-plasmid lentiviral system and co-transfected into 293T cells for virus packaging to obtain LAPTM5-sgRNA-Puro lentivirus; Step 4): Transfect HCC-LM3 cells with Cas9-Blastin lentivirus to construct HCC-LM3-Cas9 monoclonal cell line; Step 5): The HCC-LM3-Cas9 monoclonal cell line is transfected with the LAPTM5-sgRNA-Puro lentivirus obtained in step 3), positive cells are screened using puromycin, and monoclonal cells are isolated and cultured to obtain a liver cancer cell line with stable knockout of the LAPTM5 gene.

6. A liver cancer cell line with stable knockout of the LAPTM5 gene constructed by the construction method of claim 4 or 5.

7. Use of the liver cancer cell line with stable knockout of the LAPTM5 gene according to claim 6 in constructing a model for studying the function of the LAPTM5 gene.

Citation Information

Cited By

  • Method for constructing liver cancer cell line through stable expression of DeltaNp63alpha and application of liver cancer cell line

    CN119709873A